Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Anavex Lf SC (AVXL)

Anavex Lf SC (AVXL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot AP - Mon Feb 9, 6:35AM CST

Anavex Life Sciences: Fiscal Q1 Earnings Snapshot

AVXL : 4.12 (+1.98%)
Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update GlobeNewswire - Mon Feb 9, 6:30AM CST

Company to host a  webcast today at 8:30 am Eastern Time NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...

AVXL : 4.12 (+1.98%)
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 GlobeNewswire - Tue Feb 3, 6:30AM CST

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

AVXL : 4.12 (+1.98%)
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease GlobeNewswire - Tue Jan 13, 6:30AM CST

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), today announced its participation as a key industry partner in ACCESS-AD, a...

AVXL : 4.12 (+1.98%)
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm PR Newswire - Thu Jan 8, 7:13PM CST

NEWTOWN, Pa. , Jan. 8, 2026 /PRNewswire/ -- Edelson Lechtzin LLP  is investigating potential violations of the federal securities laws involving Anavex Life Sciences Corp. ("Anavex") (NASDAQ:...

AVXL : 4.12 (+1.98%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL PR Newswire - Thu Jan 8, 9:00AM CST

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are...

AVXL : 4.12 (+1.98%)
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology GlobeNewswire - Thu Jan 8, 6:30AM CST

NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

AVXL : 4.12 (+1.98%)
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program GlobeNewswire - Tue Jan 6, 6:30AM CST

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

AVXL : 4.12 (+1.98%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL PR Newswire - Thu Jan 1, 9:00AM CST

NEW YORK , Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Anavex Life Sciences Corp.  ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors...

AVXL : 4.12 (+1.98%)
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion GlobeNewswire - Thu Dec 18, 2025

NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

AVXL : 4.12 (+1.98%)

Barchart Exclusives

Kraft Heinz Pauses Its Breakup Plans. Should You Buy the High-Yield Dividend Stock Here? Barchart - Thu Feb 19, 6:30PM CST
Kraft Heinz is still facing many tough challenges. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot